Academia, industry and the slow adoption of new treatments.
Where this comes from
- Record sourced from PubMed, PMID 40796351.
- Also identified by DOI 10.1093/brain/awaf295 and PMC identifier 12677017.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Klein <i>et al</i>. discuss the academia-pharma industry gap and its impact on patient care, arguing that the severing of academic collaboration with industry has caused a drop in academic participation in clinical trials, delayed adoption of new treatments, and harmed patients. They suggest a patient-centred approach to academia-industry relations.